Abstract
In preclinical and human epidemiological and intervention trials, palmitoleic acid (POA) has shown anti-inflammatory and lipid lowering effects linked to prevention of metabolic syndrome including cardiovascular disease and insulin resistance associated with diabetes and obesity. Similar benefits have been reported following AMPK activation suggesting a convergent mode of action. A comparison of POA supplementation metabolic effects and AMPK activation impact reveals a multitude of similarities. This observation suggests that POA could be exerting at least some of its beneficial effects through AMPK activation. Preclinical studies have reported increased cellular AMPK transcription and activated AMPK levels and activity following POA treatment. A plausible explanation of how POA may activate AMPK has been reported. Further research will establish the role of POA in AMPK activation and its effects on specific biochemical activities, overall metabolism and health.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
